comprehensive -WSS

comprehensive

author：fashion 2025-10-02 05:01:18 - browse：4441

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Group opposing PBM reform sets lobbying record

WSS

J&J reports mixed data on next

Why some fertility treatments produce more boy babies

Biden tests positive for Covid

Unmasking the 'centricity' illusion in clinical trials

Clinicians often fail to acknowledge the pain caused by long Covid

FDA approves RSV monoclonal antibody for infants, toddlers

leisure time

comprehensive

hotspot

Affirmative action in medical school literally saved lives

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At Orexo, a ‘turning point’ for everything but digital health

Affirmative action in medical school literally saved lives

Protect nursing home residents from future pandemics

Peter Hotez and the public health issue of online harassment

The Bio Revolution is changing business and society

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Startup Neumora takes a novel depression drug to Phase 3

entertainment

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

In early work, researchers turn to CRISPR to treat Alzheimer's

Guardant Health colon cancer test endorsed by FDA advisory panel

Hospitals need to get ahead of regulations on climate change

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Sanders adds drug shortage policies to pandemic preparedness bill

focus

knowledge

hotspot

leisure time